Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
CompletedPhase 4NCT02977208
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study aims to evaluate the influence of genetic polymorphisms of OCTN1 and OCT2 and other possible covariates on the kinetic disposition of GAB in patients undergoing GAB chronic treatment. Thus, patients treated with GAB, for at least one week, are being investigated.
Study details
- Official title
- Impact of Genetic Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use of the Drug
- Conditions
- Interventions
- Procedure: Sparse blood sampling
- Procedure: Urine sampling
- Procedure: DNA extraction
- Drug: Gabapentin
- Sponsor
- São Paulo State University
- Collaborators
- University of Sao Paulo
- Start date
- 2016-09
- Primary completion
- 2018-02
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Brazil
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with 18 years old or older, both gender. * Patients undergoing chronic use of gabapentin (at least one week). Exclusion Criteria: * Pregnant and lactating patients. * Patients who were in use of OCT2 and OCTN1 inhibitors. * Patients who disagree to continue the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02977208